Geriatrics addresses the health needs of older adults, focusing on frailty, dementia, falls, and chronic disease management.
Send us all your questions or requests, and our expert team will assist you.
Heart Failure (HF) is no longer viewed as a sudden mechanical collapse, but as a chronic, progressive “Syndrome of Cellular Exhaustion.” It is a state where the heart muscle either loses its contractile power or its ability to relax and fill. At Liv Hospital, we shift the clinical perspective from merely managing fluid to Biological Repair, addressing the underlying loss of healthy heart tissue through regenerative insights.
When the heart weakens, the body activates survival mechanisms that lead to Ventricular Remodeling a destructive change in the heart’s geometry. This process results in wall thinning or pathological thickening, driven by neurohormonal overdrive and the buildup of stiff collagen known as fibrosis.
Our approach utilizes the paracrine hypothesis, where biological agents signal the heart to stop scarring and start repairing. By introducing regenerative signals, we aim to inhibit cell death and stimulate angiogenesis (the growth of new blood vessels) to restore oxygen delivery to hibernating heart tissue.
The clinical manifestation of heart failure involves a spectrum of symptoms that reflect the heart’s inability to meet metabolic demands. Recognizing these signs early is essential for preventing rapid functional decline and metabolic inflexibility within the cardiac cells.
Heart failure is categorized by the Left Ventricular Ejection Fraction (LVEF). We distinguish between HFrEF (Reduced EF), where the heart is weak and dilated, and HFpEF (Preserved EF), where the heart is stiff and cannot fill properly. Each phenotype requires a unique personalized medicine strategy.
To tailor heart failure treatment effectively, we must define the heart’s specific “Phenotype.” This classification moves beyond a simple diagnosis, focusing on the heart’s functional capacity and its ability to pump or fill. At the center of this evaluation is the Left Ventricular Ejection Fraction (LVEF), which measures the percentage of blood the heart pumps out with each beat.
HFrEF (Reduced EF): Systolic failure where the EF is below 40%. The heart is weak and dilated, making it the primary target for ventricular remodeling reversal and cellular therapies.
HFpEF (Preserved EF): Diastolic failure where the EF is 50% or higher. The heart is stiff and cannot fill properly, requiring focus on reducing fibrosis and improving muscle flexibility.
HFmrEF (Mildly Reduced EF): A transition zone with an EF between 41% and 49%, representing a “grey area” that requires precise metabolic monitoring and early regenerative signaling.
Heart failure is a spectrum divided into four stages (A through D). Identifying the “Therapeutic Window” is essential; for instance, Stage B (Pre-Heart Failure) is the critical window where structural changes exist without symptoms, allowing for early intervention to preserve the heart’s anatomical reserve.
Heart Failure with Reduced Ejection Fraction, often referred to as systolic heart failure, occurs when the left ventricle becomes too weak to pump blood effectively to the rest of the body. In this condition, the ejection fraction is 40% or less, meaning the heart is struggling to meet the systemic demands for oxygenated blood. At Liv Hospital, we treat HFrEF as a target for ventricular remodeling reversal, focusing on restoring the heart’s contractile strength.
In HFrEF, the heart muscle often becomes thin and dilated, a process driven by chronic neurohormonal overdrive. This structural stretching leads to a loss of “elastic recoil,” causing blood to pool in the chambers rather than being ejected. Regenerative insights aim to stop this expansion by addressing the underlying extracellular matrix decay and the loss of healthy cardiomyocytes that define the condition’s progression.
Treatment for HFrEF focuses on biological restoration to improve the heart’s “squeeze” and overall efficiency. We utilize therapeutic strategies designed to modulate inflammation and stimulate angiogenesis, providing the necessary blood flow for “hibernating” heart tissue to regain function. The ultimate goal is to improve the ejection fraction and restore the patient’s functional independence through targeted cellular rejuvenation.
A precise evaluation is the cornerstone of effective cardiac care. We utilize advanced diagnostics to identify the “Therapeutic Window,” ensuring that interventions are applied before structural damage becomes irreversible.
We categorize heart failure from Stage A (High Risk) to Stage D (Advanced). Identifying patients in the Pre-Heart Failure stage (Stage B) provides a critical window for preventative regenerative signaling to halt structural decay before symptoms even appear.
Our philosophy for treating heart failure is “Active Restoration.” We integrate standard medical therapies with cutting-edge biological solutions to rejuvenate the failing heart muscle.
When conservative and biological methods reach their limit, we transition to advanced surgical solutions. This includes specialized pacing devices or mechanical support, always integrated with a focus on preserving the remaining anatomical reserve of the myocardium.
Prevention is focused on Epigenetic Prevention managing risk factors today to alter the heart’s future. By shielding the heart from unnecessary stress, we can significantly influence its mechanical age.
Just as in joint health, we emphasize protecting the “cellular substrate” of the heart. Maintaining a healthy weight and avoiding toxins like tobacco are essential “insurance policies” for long-term functional independence.
Send us all your questions or requests, and our expert team will assist you.
A heart attack, technically known as a myocardial infarction, is an acute event caused by the sudden blockage of a coronary artery, which cuts off blood flow to a section of the heart muscle and causes tissue death. Heart failure is a chronic condition that often develops as a long-term consequence of the damage caused by a heart attack. While the heart attack is the initial injury, heart failure is the resulting syndrome where the weakened heart struggles to pump efficiently over time.
The human heart has a very low intrinsic regenerative capacity compared to organs like the skin or liver. While there is a slow turnover of cardiomyocytes throughout a person’s life, this natural process is insufficient to repair the massive amount of tissue lost during a heart attack or the chronic cell death seen in heart failure. This biological limitation is the primary driver of research and development into stem cell therapies aimed at boosting this reparative capacity.
Ejection fraction is a measurement, expressed as a percentage, of how much blood the left ventricle pumps out with each contraction. A normal ejection fraction is typically between fifty and seventy percent. This number is the most critical metric for classifying heart failure, determining its severity, guiding medication choices, and establishing eligibility for advanced therapies such as implantable defibrillators or regenerative clinical trials.
While the term reversed must be used with caution, regenerative therapies have shown the potential to improve heart function and structural parameters in clinical studies. The goal of these treatments is to reduce scar tissue and improve the function of the remaining muscle, which can increase ejection fraction and reduce symptoms. However, the degree of improvement often depends on the severity of the disease and the viability of the remaining tissue.
The term congestive heart failure is used because one of the most common features of the condition is congestion, or fluid retention. As the heart’s pumping ability declines, blood backs up in the venous system, causing fluid to leak into the lungs (pulmonary edema) and other body tissues (peripheral edema). This leads to symptoms such as shortness of breath and leg swelling, which are the hallmarks of the congestive phase of the syndrome.
Your Comparison List (you must select at least 2 packages)
